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Abstract  
BACKGROUND: Although PET-scan is an advanced, innovative and widely used method for monitoring patients 
with different types of cancer diseases, it is important to note that its application in patients with cutaneous 
melanoma is limited and should be reconsidered. 
CASE REPORT: To affirm this new statement, we are presenting a case from our clinical practice of a patient 
with melanoma of the interdigital space (with resected in sano primary melanoma and performed complete 
lymphadenectomy) that showed locoregional and systemic progression in two months post operation. The PET 
scan performed within the second hоspitalization (and before the second operation) did not detect the presence of 
any cutaneous metastases, which were clinically and histologically verified after the second operative procedure.  
CONCLUSIONS: This data suggests that shortly more reliable and sensitive imaging methods for monitoring 
patients with cutaneous melanoma should be found. Having in mind that our patient has been operated twice in 
the area of the primary lesion (as the surgical wound underwent secondary healing), theoretically, the abundant 
cicatrization could have led to reduced glucose uptake in the surrounded cancerous tissue. Monitoring of a larger 
number of patients with locoregional metastases and surgical interventions in different locations would shed light 
on the observations shared by us. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Positron emission tomography (PET) is a non-
invasive nuclear imaging technique with 
uncomparable ability to assess functional and 
biochemical processes in tissues [1]. Due to its high 
sensitivity and specificity, it has a wide application in 
oncology for cancer diagnosis, staging, restaging, 
detection of the extent of local and regional disease 
spread, as well as in the monitoring of response to 
cancer treatment [2]. An important feature of PET is 
its ability to detect the earliest stages of many 
diseases due to its possibility to assess the 
biochemical and functional processes in tissues. This 
great advantage of PET explains the importance of 
the method to the clinical oncology practice [3]. It is 
important to emphasise that this characteristic 
significantly differs it from other high sensitivity 
methods like MRI (magnetic resonance imaging) and 
CT (computer tomography), which detect only 
anatomical or functional changes that have already 
occurred [4]. 
Specifically, about melanoma malignum, 
FDG-PET takes an important place in its detection 
and imaging [5].  
 
 
Case report 
 
A 58-year-old male patient presented to the 
department of dermatologic surgery because of the 
dark lesion on his right foot. Clinical examination 
revealed a dark brown to black pigmented macula, 
located in the interdigital space between the first and 
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the second finger of the right foot, with uneven 
distribution of colour and irregular borders. The lesion 
was removed by surgical excision under local 
anaesthesia, with 0.5 cm field of safety margins in all 
directions. Also, a lymph node dissection under 
general anaesthesia was performed with 
retroperitoneal entrance toward the iliac and femoral 
vessels. Intraoperatively were established dark 
coloured packages of enlarged lymph nodes with a 
firm texture and a diameter of 2.5 cm. Enlarged lymph 
nodes were observed in the obturator whole, with the 
same characteristic. A lymph node was found in the 
pelvis immediately adjacent to the v. iliaca external, 
infiltrated the vein wall. Radical lymph dissection was 
performed in a femoral, obturator and paraphiliac 
area.  
Histological examination of the cutaneous 
lesion revealed moderately atypical cells with 
vesiculous nuclei, suspicious for melanoma, with 
tumour thickness 2 mm (Breslow).  
Histological examination of the dissected 
lymph nodes verified total and non-total metastasis 
from melanoma, some with capsular infiltration, some 
of them without.  
The patient was diagnosed in stage IIIC and 
referred for a PET-scan in 2 months. Two months 
later the patient presented to the department with two 
pigmented lesions with uneven borders in the same 
location (Fig. 1a).  
 
Figure 1: A, B) Clinical manifestation of interdigital malignant 
melanoma cutaneous metastases; C) Postoperative results after the 
second excision of a primary tumour, followed again with secondary 
healing; D) Surgical excision of the interdigital cutaneous 
metastases under local anaesthesia. Disinfection intraoperatively 
with povidone-iodine solution 10% 
 
Preoperatively, PET-scan examination was 
performed, and it detected one right prevertebral 
lymph node (L3), measured 10mm with SUVmax 3.2; 
three enlarged paraaortic lymph nodes at the level of 
the bifurcation, measured up to 13 x 6 mm with 
SUVmax up to 4.9; and distal right parailiac lymph 
nodes, measured up to 17 x 10 mm with SUVmax 
10.0. Infiltrative, probably inflammatory parenchymal 
changes of the right lung in the interlobe and 
paracardial with SUVmax up to 2.6 were also 
observed. However, no cutaneous metastases were 
detected on the PET-scan.  
The cutaneous lesions were removed by 
surgical excisions, and the histological examination 
verified nodular melanoma malignum 1cm in diameter, 
with no ulceration; mitoses 1-2; Clark II-III; Breslow – 
2.  
By the clinical results, a restaging is 
performed in stage IV. The patient was referred for 
therapy with Pembrolizumab (KEYTRUDA) after 
hospitalisation in the oncology department.  
 
 
Discussion 
 
Nowadays, malignant melanoma is showing a 
tendency to increase in incidence – since 1970 it has 
approximately doubled with an estimated 68,720 new 
diagnosed in 2009 [6]. Early stages of melanoma are 
effectively treated with surgical excision [7]. However, 
by the time of diagnosis 15% of patients are 
presented with metastases or locally advanced tumor 
process [8].   
FDG-PET has a wide application in oncology 
because of its significant role in cancer diagnosis, 
staging, restaging and therapeutic response 
monitoring in the most common cancers [9]. FDG 
(fluorodeoxyglucose) is an analog of glucose used as 
a radiotracer in order to detect tumor cells which are 
distinguished to have elevated glucose uptake [10].  It 
is a well-known fact that tumor cells have high 
metabolic needs of glucose, lipids and amino acids. 
PET imaging is based exactly on this distinctive 
feature of tumors, which explains the high sensitivity 
and specificity of the method when it refers to cancer 
diagnosis, staging and therapeutic response 
monitoring [11]. Glucose, as well as oxygen, growth 
factors and nutrients are critical factors that ensure 
the progress of cancer cells into solid tumors by 
activating their specific metabolic pathaways [12]. 
Microenvironment, especially hypoxia takes important 
place in the evolution of tumors [13]. In hypoxic 
conditions of 100-150 μm distance between the tumor 
cells and the nearest blood vessel, their ability to 
endure profound hypoxia is condition for their 
progress [14]. An adapting mechanism of cancerous 
cells is the ability to rely on anaerobic glucose 
metabolism, which ensures the major needs of energy 
for tumour growing [15]. 
Nowadays, PET takes a significant place in 
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oncology where it is widely used for cancer diagnostic, 
staging and therapy response monitoring [16]. Soon, 
in 1998, the limitations of PET were overcome with 
the development of the first combined PET/CT, firstly 
installed in University of Pittsburgh Medical Center 
[17]. This imaging technique provides an assessment 
of both biochemical and anatomic characteristics of 
tissues and is a significant advance in the evaluation 
of primary tumours, metastases, staging, therapy 
response monitoring and post-treatment recidives 
[18]. 
FDG-PET has a large application in 
evaluation of the extent of local and regional disease 
spread [19, 20]. Results of a meta-analysis evaluating 
the ability of PET in staging and restaging of 
cutaneous melanoma confirmed its usefulness in the 
detection of distant metastases. However, not so 
desirable results were observed in the evaluation 
accuracy of regional metastases as it does not detect 
microscopic disease [21]. Another report of Crippa et 
al. affirms reliable sensitivity and specificity in 
detection of lymph node metastases in patients with 
malignant melanoma. The presented results are 
showing that FDG-PET detected 100% of metastases 
≥10 mm, 83% of metastases 6-10 mm, and 23% of 
metastases ≤ 5 mm. It is important to emphasise that 
the FDG-PET had high sensitivity (> or = 93%) only 
for metastases with more than 50% lymph node 
involvement or with capsular infiltration. However, this 
imaging method is not sensitive enough to detect 
subclinical microscopic disease [22]. The fact that 
PET sensitivity for melanoma lymph node metastases 
is dependent on tumour volume is also reported in 
data presented by Wagner et al. [23] 
However, despite the successful results of 
PET in cancer diagnosis and evaluation, it has some 
important limitations that should not be neglected: (1) 
no quantitative system in assessing changes in FDG-
metabolism in the therapeutic response. In the USA 
the development of such system is based on PET 
Response Criteria in Solid Tumors (PERCIST) [24]; 
(2) False-positive results. False positive results are 
possible because of increased FDG uptake in some 
normal body areas, such as lymphoid tissue and 
brown adipose tissue [25]. Another reason for false 
positive results may be the increased accumulation of 
FDG in some benign processes as inflammation or 
infection [26]; (3) low sensitivity. Low sensitivity may 
be observed in hypocellular cancers such as 
desmoplastic or mucinous tumours, as well as in 
micrometastases in breast cancer and melanoma [27]. 
Also, PET presents low sensitivity in well-
differentiated low-grade tumours, which have lower 
glucose uptake, such as carcinoid tumours, renal cell 
carcinoma, bronchoalveolar-cell carcinoma and most 
prostate cancers [28].   
We present a case of a patient with a 
malignant melanoma where two satellite cutaneous 
metastases measured 2 x 0.7 cm were not detected 
via PET-scan examination. With the presented case 
we want to report the unreliable results of PET-
imaging when it refers to cutaneous melanoma 
metastases.  
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